Evidence map›Paper›PMID 24893707›Full record

ArticleBrain : a journal of neurology2014

Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics.

Oscar G Vidaurre, Jeffery D Haines, Ilana Katz Sand, Kadidia P Adula, Jimmy L Huynh, Corey A McGraw, Fan Zhang, Merina Varghese, Elias Sotirchos, Pavan Bhargava and 10 more

Erratum issued Registry-linked trialOpen access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Brain : a journal of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03092544 (Investigating Indirect Mechanism of Neuroprotection of Tecfidera®), which is not on this map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03092544 phase4unknown statusnot on this mapstarted 2015, after this paper: background citation

Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients

TypeinterventionalSponsorMultiple Sclerosis Center of Northeastern New YorkRan2015 to 2018Enrolled57ConditionsMultiple SclerosisArmsdimethyl fumarate
3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 154 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Oxidative Stress Markers in Multiple Sclerosis.International journal of molecular sciences · 2024
    Review
  17. Review
  18. Article
  19. Review
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Oscar G Vidaurre1 Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jeffery D Haines1 Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ilana Katz Sand2 Corinne Goldsmith Dickinson Centre for MS, Mount Sinai Medical Centre, New York, NY 10029, USA.
Kadidia P Adula1 Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jimmy L Huynh1 Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Corey A McGraw3 Department of Neurology, Albert Einstein College of Medicine, Montefiore Medical Centre, Bronx, NY, USA.
Fan Zhang4 Bioinformatics Department, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Merina Varghese5 Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Elias Sotirchos6 Department of Neurology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Pavan Bhargava6 Department of Neurology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Veera Venkata Ratnam Bandaru6 Department of Neurology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Giulio Pasinetti5 Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Weijia Zhang4 Bioinformatics Department, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Matilde Inglese7 Department of Neurology, Radiology and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Peter A Calabresi6 Department of Neurology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Gang Wu8 Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Aaron E Miller2 Corinne Goldsmith Dickinson Centre for MS, Mount Sinai Medical Centre, New York, NY 10029, USA.
Norman J Haughey6 Department of Neurology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Fred D Lublin2 Corinne Goldsmith Dickinson Centre for MS, Mount Sinai Medical Centre, New York, NY 10029, USA.
Patrizia Casaccia1 Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA patrizia.casaccia@mssm.edu.
Icahn School of Medicine at Mount Sinai · USJohns Hopkins Hospital · USAllen Institute for Brain Science · USAlbert Einstein College of Medicine · US

Funding

Molecular Mechanism of Neuronal Damage in Demyelinating DisordersR01NS069835 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CASACCIA, PATRIZIA · 2011 to 2014
$1.5M
NINDS NIH HHS R01 NS069835NINDS NIH HHS R01NS69835
6 · The paper itself

Abstract

Axonal damage is a prominent cause of disability and yet its pathogenesis is incompletely understood. Using a xenogeneic system, here we define the bioenergetic changes induced in rat neurons by exposure to cerebrospinal fluid samples from patients with multiple sclerosis compared to control subjects. A first discovery cohort of cerebrospinal fluid from 13 patients with multiple sclerosis and 10 control subjects showed that acute exposure to cerebrospinal fluid from patients with multiple sclerosis induced oxidative stress and decreased expression of neuroprotective genes, while increasing expression of genes involved in lipid signalling and in the response to oxidative stress. Protracted exposure of neurons to stress led to neurotoxicity and bioenergetics failure after cerebrospinal fluid exposure and positively correlated with the levels of neurofilament light chain. These findings were validated using a second independent cohort of cerebrospinal fluid samples (eight patients with multiple sclerosis and eight control subjects), collected at a different centre. The toxic effect of cerebrospinal fluid on neurons was not attributable to differences in IgG content, glucose, lactate or glutamate levels or differences in cytokine levels. A lipidomic profiling approach led to the identification of increased levels of ceramide C16:0 and C24:0 in the cerebrospinal fluid from patients with multiple sclerosis. Exposure of cultured neurons to micelles composed of these ceramide species was sufficient to recapitulate the bioenergetic dysfunction and oxidative damage induced by exposure to cerebrospinal fluid from patients with multiple sclerosis. Therefore, our data suggest that C16:0 and C24:0 ceramides are enriched in the cerebrospinal fluid of patients with multiple sclerosis and are sufficient to induce neuronal mitochondrial dysfunction and axonal damage.

Indexed as

AdolescentAdultAgedAged, 80 and overAnimalsCells, CulturedCeramidesCohort StudiesEnergy MetabolismHumansMiddle AgedMultiple SclerosisNeuronsRatsRats, Sprague-DawleyYoung AdultCeramidesaxonal degenerationdemyelinating diseaselipid metabolismmitochondrianeurodegenerative mechanism

Identifiers

PMID24893707
PMCPMC4164163
OpenAlexW2087968417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.